Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116,292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
Stock S, Übelhart R, Schubert ML, Fan F, He B, Hoffmann JM, Wang L, Wang S, Gong W, Neuber B, Hückelhoven-Krauss A, Gern U, Christ C, Hexel M, Schmitt A, Schmidt P, Krauss J, Jäger D, Müller-Tidow C, Dreger P, Schmitt M, Sellner L. Stock S, et al. Among authors: wang l, wang s. Int J Cancer. 2019 Sep 1;145(5):1312-1324. doi: 10.1002/ijc.32201. Epub 2019 Feb 28. Int J Cancer. 2019. PMID: 30737788
Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells.
Wang L, Gong W, Wang S, Neuber B, Sellner L, Schubert ML, Hückelhoven-Krauss A, Kunz A, Gern U, Michels B, Hinkelbein M, Mechler S, Richter P, Müller-Tidow C, Schmitt M, Schmitt A. Wang L, et al. Among authors: wang s. Cytotherapy. 2019 May;21(5):566-578. doi: 10.1016/j.jcyt.2019.02.013. Epub 2019 Mar 23. Cytotherapy. 2019. PMID: 30910382
Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies.
Yoo HJ, Liu Y, Wang L, Schubert ML, Hoffmann JM, Wang S, Neuber B, Hückelhoven-Krauss A, Gern U, Schmitt A, Müller-Tidow C, Dreger P, Mokhir A, Schmitt M, Sellner L. Yoo HJ, et al. Among authors: wang l, wang s. Int J Mol Sci. 2019 May 18;20(10):2469. doi: 10.3390/ijms20102469. Int J Mol Sci. 2019. PMID: 31109083 Free PMC article.
Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells.
Yang M, Wang L, Ni M, Neuber B, Wang S, Gong W, Sauer T, Sellner L, Schubert ML, Hückelhoven-Krauss A, Hong J, Zhu L, Kleist C, Eckstein V, Müller-Tidow C, Dreger P, Schmitt M, Schmitt A. Yang M, et al. Among authors: wang l, wang s. Front Immunol. 2020 Dec 9;11:608167. doi: 10.3389/fimmu.2020.608167. eCollection 2020. Front Immunol. 2020. PMID: 33362794 Free PMC article.
Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy.
Yang M, Wang L, Ni M, Neuber B, Wang S, Gong W, Sauer T, Schubert ML, Hückelhoven-Krauss A, Xia R, Ge J, Kleist C, Eckstein V, Sellner L, Müller-Tidow C, Dreger P, Schmitt M, Schmitt A. Yang M, et al. Among authors: wang l, wang s. Front Immunol. 2021 May 26;12:670088. doi: 10.3389/fimmu.2021.670088. eCollection 2021. Front Immunol. 2021. PMID: 34122428 Free PMC article.
CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
Liu Y, Wang S, Schubert ML, Lauk A, Yao H, Blank MF, Cui C, Janssen M, Schmidt C, Göllner S, Kleist C, Zhou F, Rahfeld JU, Sauer T, Schmitt M, Müller-Tidow C. Liu Y, et al. Among authors: wang s. Int J Cancer. 2022 Apr 1;150(7):1141-1155. doi: 10.1002/ijc.33865. Epub 2021 Nov 23. Int J Cancer. 2022. PMID: 34766343
116,292 results
You have reached the last available page of results. Please see the User Guide for more information.